Phase II study of 5-FU dose-adjusted mFOLFOX7 plus Bevacizumab for patients with metastatic colorectal cancer

Trial Profile

Phase II study of 5-FU dose-adjusted mFOLFOX7 plus Bevacizumab for patients with metastatic colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms A-JUST
  • Most Recent Events

    • 01 Dec 2016 Status changed from active, no longer recruiting to completed as per results published in the Cancer Chemotherapy and Pharmacology.
    • 01 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 09 Jun 2012 Additional lead investigator (Hideyuki Mishima) identified as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top